http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Anne L. Versteeg,Lior M. Elkaim,Arjun Sahgal,Laurence D. Rhines,Daniel M. Sciubba,James M. Schuster,Michael G. Fehlings,Aron Lazary,Michelle J. Clarke,Paul M. Arnold,Chetan Bettegowda,Stefano Boriani 대한척추신경외과학회 2022 Neurospine Vol.19 No.1
Objective: Patients presenting with neurological deficit secondary to metastatic epidural spinal cord compression (MESCC) are often treated with surgery in combination with high-dose corticosteroids. Despite steroids being commonly used, the evidence regarding the effect of corticosteroids on patient outcomes is limited. The objective of this study was to describe the effect of corticosteroid use on preoperative neurological function in patients with MESCC. Methods: Patients who underwent surgery between August 2013 and February 2017 for the treatment of spinal metastases and received steroids to prevent neurologic deficits were included. Data regarding demographics, diagnosis, treatment, neurological function, adverse events, health-related quality of life, and survival were extracted from an international multicenter prospective cohort. Results: A total of 30 patients treated surgically and receiving steroids at baseline were identified. Patients had a mean age of 58.2 years (standard deviation, 11.2 years) at time of surgery. Preoperatively, 50% of the patients experienced deterioration of neurological function, while in 30% neurological function was stable and 20% improved in neurological function. Lengthier steroid use did not correlate with improved or stabilized neurological function. Postoperative adverse events were observed in 18 patients (60%). Patients that stabilized or improved neurologically after steroid use showed a trend towards improved survival at 3- and 24-month postsurgery. Conclusion: This study described the effect of steroids on preoperative neurological function in patients with MESCC. Stabilization or improvement of preoperative neurological function occurred in 50% of the patients.
Anne-Maree O’Rourke,Francois A. Carrillat 글로벌지식마케팅경영학회 2016 Global Marketing Conference Vol.2016 No.7
A product’s competitive position (CP) identifies the segment the product is targeting and the value proposition it offers that differentiates it from its competitors (Hooley & Greenley, 2005). Having a clear, strong competitive position for products in the mind of the consumer, known as the perceived position, is considered to be absolutely imperative for products to compete in today’s market. In order to get to this evaluation or judgment on the product’s position, consumers need to sift through the ever-growing availability of organization and market-derived information. Consumer behavior literature dictates that such a judgment would have a level of confidence attached to it, specifically known as belief-confidence. Extensive literature has empirically linked belief-confidence to purchase intention (Bennell & Harrell, 1975; Howard & Steth, 1969; Laroche, Kim, & Zhou, 1995; Russo, Medvec, & Melov, 1996), however the construct has not been examined relative to the strategic concept of competitive product positioning. This research proposes a framework that suggests when the consumer’s perceived position for a product matches their purchase goal, [for example a consumer is seeking a ‘top of the range’ personal laptop and after evaluating laptop alternatives in the market judges product X as the ‘top of the range’ offering] the consumer’s confidence in their positioning judgment acts as a moderator, magnifying its ultimate effect on purchase intention. Given that judgment confidence is context specific (Chandrashekaran, Rotte & Grewal, 2005), this research suggests three antecedents to consumers’ confidence in competitive positions of products (1) position clarity (2) position consistency (3) alignment between the initial and post (information search) perceived positions. Support for these antecedents stems from various fields of literature including positioning implementation; consumer perception; judgment revision; information distortion and brand equity signaling (Erdem & Swait, 1998; Muthukrishnam, 2002; Russo, Medvec, & Melov, 1996; Crawford, 1985). Two between-subjects factorial experiments entailing a mock information search designed to manipulate (1) and (2) of the proposed antecedents will be administered online, whereby total n=540. Measures taken pre and post the experiment will enable validation of the remaining variables in the conceptual model. This research aims to show that adding a confidence measure to positioning measurement such as perceptual mapping, is a better predictor of purchase intention (when coupled with purchase goal), than positioning measurement alone. It ultimately gives managers an insight into what drives consumers’ confidence in deciphering what a product stands for amongst its competitors.
Ann-Yae Na,Eun-Ju Yang,Ju Mi Jeon,Sung Hwan Ki,Kyung-Sik Song,Sangkyu Lee 한국독성학회 2018 Toxicological Research Vol.34 No.1
Ethanol-induced fat accumulation, the earliest and most common response of the liver to ethanol exposure, may be involved in the pathogenesis of liver diseases. Isoliquiritigenin (ISL), an important constituent of Glycyrrhizae Radix, is a chalcone derivative that exhibits antioxidant, anti-inflammatory, and phytoestrogenic activities. However, the effect of ISL treatment on lipid accumulation in hepatocytes and alcoholic hepatitis remains unclear. Therefore, we evaluated the effect and underlying mechanism of ISL on ethanol-induced hepatic steatosis by treating AML-12 cells with 200 mM ethanol and/or ISL (0~50 μM) for 72 hr. Lipid accumulation was assayed by oil red O staining, and the expression of sirtuin1 (SIRT1), sterol regulatory element-binding protein-1c (SREBP-1c), AMP-activated protein kinase (AMPK), and peroxisome proliferator-activated receptor alpha (PPARα) was studied by western blotting. Our results indicated that ISL treatment upregulated SIRT1 expression and downregulated SREBP-1c expression in ethanol-treated cells. Similarly, oil red O staining revealed a decrease in ethanolinduced fat accumulation upon co-treatment of ethanol-treated cells with 10, 20, and 50 μM of ISL. These findings suggest that ISL can reduce ethanol induced-hepatic lipogenesis by activating the SIRT1-AMPK pathway and thus improve lipid metabolism in alcoholic fatty livers.
A Public Perception Study on the new word "Corona Blue":Focusing on Social Media Big Data Analysis
Ann, Myung Suk The International Promotion Agency of Culture Tech 2020 International Journal of Advanced Culture Technolo Vol.8 No.3
The purpose of this study is to contribute to the provision of basic data for psychological quarantine policy and counseling by examining the public perception of the "corona blue" phenomenon through analysis of social media big data. To do this, key words related to the word 'Corona Blue' were derived and analyzed using the big data analysis program 'Textom'. As a result of the analysis, words such as 'Corona 19', 'depression', 'problem' and 'overcome' were derived as key words. For the analysis results,"pride and awarenes as the public perception of Corona 19", "depression and anxiety as a group trauma as the corona blue phenomenon", "spreading a psychological quarantine culture and demanding social healing as the perception of overcoming corona Blue," and "hope for return to daily life and changes in daily life as the perception of post corona" were discussed. In conclusion, we have identified the need for active psychological support from the community By revealing that Corona Blue is a depression as a group trauma. At this time, it is confirmed that it is necessary to prioritize social healing and psychological quarantine for the main risk groups such as youth or the vulnerable, who are the socially weak.
Anne E Olesen,Debbie Grønlund,Esben B Mark,Klaus Krogh,Jens B Frøkjær,Asbjørn M Drewes 대한소화기 기능성질환∙운동학회 2019 Journal of Neurogastroenterology and Motility (JNM Vol.25 No.4
Background/Aims Opioids cause gastrointestinal (GI) dysmotility, decrease gut secretion, and affect gut sphincters. Symptoms of opioid-induced bowel dysfunction may be alleviated by peripherally acting opioid antagonists like naloxegol, but detailed knowledge on GI effects of this drug is lacking. We hypothesized that naloxegol, compared to placebo, would reduce GI transit time and colonic fecal volume in opioid-treated healthy participants. Methods We conducted a randomized, double-blinded, single-center, 2-way cross-over study in 24 healthy males, randomized to a 6 day treatment period of oxycodone (15 mg twice a day) co-administered with either naloxegol (25 mg once a day) or matching placebo. Participants swallowed an electromagnetic capsule which determined GI transit times. Colonic fecal volume was quantified with magnetic resonance imaging both pre-treatment and post-treatment. Results Naloxegol reduced total GI transit time by 21% (56 hours vs 71 hours, P = 0.02) and colonic transit time by 23% (45 hours vs 59 hours, P < 0.01), compared to placebo. However, no difference in colonic fecal volume was found (818 mL vs 884 mL, P = 0.20). Conclusions Short-term administration of naloxegol in healthy participants reverses the retardation of total GI and colonic transit induced by oxycodone. This supports the use of naloxegol in the treatment of GI side effects to opioid treatment, and add knowledge to the current understanding of mechanisms behind peripherally-acting opioid antagonists.